Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12884247 | 0.81 | ATM (0.52) | ALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL10193267 | 0.81 | ATM (0.52) | ALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL9854114 | 0.81 | LMNA (0.52) | LMNAALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL4322254 | 0.81 | LMNA (0.52) | LMNAALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL3632858 | 0.81 | LMNA (0.52) | LMNAALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL13225899 | 0.79 | LMNA (0.59) | LMNAALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL891415 | 0.79 | ELANE (0.68) | LMNAALDH1A1ELANEGAAKMT2A | |
| SCHEMBL1561410 | 0.79 | LMNA (0.59) | LMNAALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL2425021 | 0.79 | LMNA (0.59) | LMNAALDH1A1ELANEL3MBTL1GAA | |
| SCHEMBL13517717 | 0.79 | LMNA (0.59) | LMNAALDH1A1ELANEL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100267734-A1 | N-[(3,5-DICHLOROPHENYL)METHYL]-2-(4-METHYL-1-PIPERAZINYL)-2-(1-NAPHTHALENYL)ETHANAMIDE AS GHRELIN RECEPTOR MODULATOR | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20100267734-A1 | N-[(3,5-DICHLOROPHENYL)METHYL]-2-(4-METHYL-1-PIPERAZINYL)-2-(1-NAPHTHALENYL)ETHANAMIDE AS GHRELIN RECEPTOR MODULATOR | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| WO-2008148856-A1 | N- ( (3, 5-DICHLOROPHENYL) METHYL) -2- U-METHYL-1-PIPERAZINYL) -2- ( 1-NAPHTALENYL) ETHAN AMIDE AS GHRELIN RECEPTOR MODULATOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267734-A1 | N-[(3,5-DICHLOROPHENYL)METHYL]-2-(4-METHYL-1-PIPERAZINYL)-2-(1-NAPHTHALENYL)ETHANAMIDE AS GHRELIN RECEPTOR MODULATOR | GHSR, GHRHR, GIPR | LMNA 3157/4885ALDH1A1 2605/4885ELANE 864/4885 |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | LMNA 4536/4885ALDH1A1 2645/4885ELANE 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.